University Health Network, Toronto: Squamous Cell Carcinoma of Head and Neck trials

The registry lists 17 Squamous Cell Carcinoma of Head and Neck studies with University Health Network, Toronto as lead sponsor. 5 are open to participants now and 0 have results posted.

Early Phase 1 1Phase 1 3Phase 2 3No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Optimizing Response to Immunotherapy With Online Adaptive Pulsed Radiotherapy in Incurable Head and Neck CancersNot yet recruitingNCT07888816Phase 2
• A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)RecruitingNCT07408063Phase 2
• HN-BIO 02: A Phase II Randomized Study of the Effects of Delayed Elective Radiotherapy on Head and Neck MRI and Immune Response BiomarkersRecruitingNCT06487403Not applicable
• A Study of Head and Neck MRI and Tumor Microenvironment BiomarkersRecruitingNCT06085781Not applicable
• HN-QUEST: A Study of Head and Neck Imaging BiomarkersRecruitingNCT05919290Not applicable
• Real-time Detection of ctDNA and/or HPV DNA in High-risk Locally-advanced Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT04599309
• A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA MethylationWithdrawnNCT04262388Phase 2
• Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma 2CompletedNCT03838601Not applicable
• Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic TherapyActive, not recruitingNCT03712566
• Biofeedback Rehabilitation to Improve Speaking and Eating in PublicCompletedNCT03650699Not applicable
• Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity StudyCompletedNCT03575598Early Phase 1
• Transoral Robotic Surgery and Tailored Radiotherapy in Unknown Primary and Small Squamous Cell Head and Neck CancerCompletedNCT03281499Not applicable
• Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral CavityWithdrawnNCT02993991Phase 1
• Head and Neck Squamous Cell Carcinoma (HNSCC)PET-CT Pilot StudyCompletedNCT02678884Not applicable
• Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck CancerCompletedNCT02537223Phase 1
• Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and NeckCompletedNCT01737008Phase 1
• A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell CarcinomaCompletedNCT01484847Not applicable